Nervous Disorder TRIZ Cases

Amifampridine blocks potassium channels to treat post-COVID fatigue without immune modulation.

Detecting ABCG2 polymorphisms identifies high-risk patients early, reducing unnecessary medical burdens from blanket urate-lowering drug prescriptions.

Deamidating asparagine 25 in interferon-beta 1a boosts immunomodulatory activity while addressing storage stability trade-offs during production.

SOX2 and HMGA2 reprogram non-neuronal cells into induced neural stem cells, bypassing pluripotent states to eliminate teratoma risks.

Segmenting synthesis into discrete steps with protected intermediaries resolves yield and stereoselectivity contradictions for this S1P1 receptor modulator.

Modified scorpion peptides optimize Kv1.3 binding affinity while maintaining structural stability for inflammatory disorder treatments.

Antibodies targeting phosphorylated TDP-43 domains mitigate neurodegeneration by reducing protein aggregation while preserving normal cellular functions.

Enzymatic extraction of Fructus lycii glucopeptide replaces synthetic levodopa to reduce side effects while treating Parkinson's disease.

Blocking receptor-mediated endocytosis via dynamin inhibitors prevents antigen internalization, resolving resistance in EGFR-positive tumors.

Short peptides bind the CD28 homodimer interface, blocking costimulatory signaling to reduce inflammatory cytokine levels and tissue damage.

Merging synthetic steps into one reaction improves chemical fidelity and efficiency, resolving the trade-off between manufacturing precision and productivity.

Antibodies targeting N-terminal truncated amyloid-beta protofibrils stabilize pathological aggregates.

Disulfide-stabilized polypeptides inhibit nAChR activity by blocking calcium responses, addressing low targeting specificity in current therapies.

Novel heterocyclyl-phenyl-methylamine derivatives act as selective S1P1 and S1P5 receptor agonists to regulate lymphocyte counts.

NMR spectroscopy measures biofluid metabolites to confirm relapses, resolving diagnostic ambiguity from pseudo-relapses.

Synthetic antibodies bind non-contiguous apoE4 epitopes, reducing neurotoxic fragment generation.

Segmented carbohydrate macromolecules deliver agents to CD206 receptors, resolving the trade-off between targeting precision and molecular complexity.

Multi-copper oxidase-derived peptides target nervous system structures to repair myelination damage in copper-induced models.

Metabolomics and genetic analysis identify mitochondrial biomarkers to stratify patients with central nervous system disorders.

Formula I compounds activate glutamate transporters to enhance neurotransmitter uptake in neuronal systems.

Intratumoral PRX 321 injections concentrate IL-4 toxins at the tumor site, expanding the therapeutic index by sparing normal tissue from systemic toxicity.

Anti-ActRIIB antibodies bind the ActRIIB receptor to block myostatin, resolving low therapeutic effectiveness in muscle wasting treatments.

Glycosylated polypeptide with uniform sialylated sugar chains extends plasma half-life.

Peptides derived from the HIV-1 p17 protein induce angiogenic activity by binding to CXCR1 and CXCR2 receptors on endothelial cells.

Targeted antibodies neutralize soluble amyloid beta ligands to prevent synaptic dysfunction, resolving poor dementia correlation from fibril-focused therapies.

Licochalcone A activates AMPK in hepatocytes, reducing triglyceride accumulation to treat fatty liver disease.

DNase I therapy targets extracellular DNA accumulation, addressing neuronal toxicity that traditional intracellular treatments fail to resolve.

Altering C1 inhibitor glycosylation reduces plasma half-life, extending the therapeutic window for stroke treatment up to 18 hours post-ischemia.

Small molecule compounds modulate Wnt, BMP, and Activin/Nodal signaling pathways to generate stable ISL1+ multipotent progenitor cells.

4-oxo-2-pentenoic acid activates Nrf2 to shield neurons against oxidative stress, overcoming low solubility limits of conventional antioxidants.

Chemical synthesis creates glycosylated polypeptides with uniform sugar chains, resolving manufacturing precision issues in interferon beta production.

Targeted pharmacokinetic profile treats major depressive disorder in patients failing first-line antidepressants.

A pump-based intravaginal ring enables adjustable drug release, resolving the trade-off between fixed duration and adaptability.

Anti-ASIC1a antibodies inhibit ASIC1a channels, reducing acid-induced cell death and brain damage in ischemic stroke.

Small molecules induce brown adipocyte progenitor differentiation into mature cells expressing UCP1.

Anti-CD20 antibodies deplete pathogenic B cells, reducing disease progression time in progressive multiple sclerosis patients.

Core molecules anchor heparin to biomaterials, preserving anti-thrombotic activity during sterilization and storage.

Secreted UBE3A vector overcomes limited rAAV transduction efficiency by diffusing protein throughout the brain to treat Angelman syndrome.

Astaxanthin-based pet food reduces excrement odor and manages blood glucose levels through natural antibacterial and antidiabetic actions.

Anti-CD52 antibody therapy depletes pathogenic lymphocytes while increasing regulatory T cell infiltration to resolve proteinuria and side effects.

Anti-exon-17 peptide antibody neutralizes periostin anti-cell adhesive activity to inhibit cell detachment.

Parabacteroides bacteria restore balance to liking, wanting, and learning components, addressing inadequate conventional therapies.

Tricyclic benzimidazole compounds with specific halogen and functional group substituents provide selective inhibitory activity against the CDK8 kinase enzyme.

Banana peel extract upregulates TPH1, DDC, and AANAT genes to boost endogenous melatonin, avoiding addiction risks from synthetic sedatives.

A valbenazine synthesis process using acetonitrile and p-toluenesulfonic acid to improve reaction homogeneity.

Fusing exendin-4 with an albumin-binding domain and anti-FcRn affibody extends plasma half-life, enabling once-weekly administration for diabetes treatment.

Structural modifications of ergoline compounds treat mood disorders while reducing abuse potential.